EnteroMedics unveils efficacy and safety results from the 1st 18 months of its 5-year ReCharge pivotal trial for its VBLOC neurostimulation therapy for treating obesity.
EnteroMedics revealed results for the 1st 18 months of its 5-year ReCharge pivotal trial for its VBLOC therapy, an implanted neurostimulator designed to help prevent obesity.
VBLOC therapy limits signals from vagus nerve, which regulates gastrointestinal and metabolic mechanisms such as expansion of the stomach as food enters. The pacemaker-like device Maestro device stimulates the nerve to alter perceptions of hunger and fullness.
